Tysabri Slump Creates Buying Edge For Long-Term Investors
When Amylin Pharmaceuticals Inc. won approval of its second diabetes drug in as many months, Byetta (exenatide), the company's stock - rather than skyrocketing, as likely would have happened in the old days - fell 6 percent.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter